Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | KMT2A rearrange |
Therapy | Revumenib |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | acute myeloid leukemia | predicted - sensitive | Revumenib | Case Reports/Case Series | Actionable | In a Phase I trial (AUGMENT-101), Revuforj (revumenib) treatment resulted in an initial response with morphological leukemia-free states in 2 patients with acute myeloid leukemia harboring KMT2A rearrangements (PMID: 36922589; NCT04065399). | 36922589 |
PubMed Id | Reference Title | Details |
---|---|---|
(36922589) | MEN1 mutations mediate clinical resistance to menin inhibition. | Full reference... |